IndyGeneUS Bio welcomed Julius Valentine M. as Strategic Advisor.

IndyGeneUS Bio is a BioFinTech company building the largest and most inclusive genomic database in the world, transforming underrepresented genomic data into Biological Capital. We are the BlackRock of Genomics, bringing equity, discovery, and economic participation to communities that have been excluded from the genomic revolution. With a rapidly expanding 700,000-plus whole-blood sample dataset and a global clinico-genomic ecosystem, we are redefining how biological data is collected, protected, valued, and reinvested back into the people it comes from. Our vision is to reach 1 million genomes and bring representation to the six billion people missing from today’s datasets. Our infrastructure includes advanced analytics, sovereign-ready governance, trusted community sampling frameworks, and a global network of researchers and health systems. By pairing community-centered stewardship with deep clinico-genomic insights, we uncover drug targets, disease pathways, and innovations that legacy datasets have overlooked. This is diversity as alpha and BioFinTech as a new category that enables secure, consent-driven economic participation. As global pharma loses more than two hundred billion dollars annually due to incomplete data, our model strengthens discovery and increases return on investment. IndyGeneUS Bio is led by Founder and CEO Yusuf Henriques, a former FDA regulator, U.S. Army combat medic, and award-winning genomics innovator. As we expand our global footprint and scale high-value relationships across pharma and biotech, we remain focused on building the world’s most trusted and most equitable clinico-genomic ecosystem, creating better health outcomes and generational equity through Biological Capital.

Founded 2025